



PHARMACEUTICAL 2020









PHARMACEUTICAL 2020





ROCKET PHARMACEUTICALS INC. Rank 79 of 362

The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 158% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Revenues, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 11%, being 314% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	307,754
Cost of Goods Sold	0
Intangible Assets	30,815
Liabilities, Current	18,309
Liabilities, Non-Current	1,466
Other Assets	4,257
Other Compr. Net Income	147
Other Expenses	5,958
Other Liabilities	45,049
Other Net Income	1,425
Property and Equipment	29,295
Research and Development	58,623
Revenues	3,414
Selling, General and Administrative Expense	17,528

Output Variable	Value in 1000 USD
Assets	372,121
Liabilities	64,824
Expenses	82,109
Stockholders Equity	307,297
Net Income	-77,270
Comprehensive Net Income	-77,196
Economic Capital Ratio	11%